First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) Stock Price

TRAXStock
$41.86
Market Cap$1.50B
P/E
PEG Ratio
Div yield
Beta1.38

TRAX Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-10.86%
VGM Score75.75

TRAX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.80-$0.95-18.37%(-$0.15)

TRAX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.25
4.21
4.21

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
TRAXFirst Tracks Biotherapeutics, Inc. Ordinary Shares
B$41.86
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About First Tracks Biotherapeutics, Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.